Why the study?
Analyzing responsiveness to P2Y12 therapy is vital to prevent thrombotic and hemorrhagic complications in patients with cardiovascular diseases, motivating the evaluation of a new Anysis-P2Y12 assay against VerifyNow-P2Y12.
Does the Anysis-P2Y12 assay perform comparably to the VerifyNow-P2Y12 assay in assessing therapeutic platelet inhibition in cardiac patients?
Population
125 citrated blood samples from cardiac patients referred for a P2Y12 antiplatelet response test
Comparison
Anysis-P2Y12 assay system vs VerifyNow-P2Y12
Design
Comparative diagnostic study
Authors
Loading...
Anysis-P2Y12 shows equivalent performance to VerifyNow; leaves open whether it improves clinical decision-making or outcomes in antiplatelet monitoring.
Does the Anysis-P2Y12 assay perform comparably to the VerifyNow-P2Y12 assay in assessing therapeutic platelet inhibition in cardiac patients?
The Anysis-P2Y12 assay demonstrates high agreement with VerifyNow-P2Y12 in terms of sensitivity and specificity, though it yields a lower rate of identified P2Y12 non-responsiveness.
Piao et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: